- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01907555
Clinical, Molecular and Physiopathological Study of Cohen Syndrome and Cohen-like Syndromes
January 30, 2018 updated by: Centre Hospitalier Universitaire Dijon
This project will make it possible to better understand the natural history of Cohen Syndrom and the phenotypes associated with mutations in the VPS13B gene, to improve the therapeutic management of patients.
It will also provide a better description of Cohen-like syndrome for genetic counselling for the families concerned.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dijon, France, 21079
- CHU de Dijon
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Cohen syndrome
Description
Inclusion Criteria:
- Patients presenting Cohen syndrome and two VPS13B mutations
- who accept a clinical evaluation, and to provide at least one blood sample
- Patients presenting the diagnostic criteria of Cohen syndrome, but without a VPS13B mutation
- Patients presenting neutropenia or pigmentary retinopathy and at least one of the following signs, after exclusion of any other syndrome: mental retardation, microcephaly, truncal obesity
Exclusion Criteria:
- - Patients who do not meet the clinical and/or molecular criteria
- Patients who do not wish to provide a blood sample for question 1,
- Patients who have not provided written informed consent,
- Pregnant or breast-feeding women,
- Persons not covered by National Health Insurance and persons under guardianship or in prison.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
|---|
|
- Patients presenting Cohen syndrome and two VPS13B mutations
|
|
Patients presenting Cohen syndrome without a VPS13B mutation
|
|
Patients presenting neutropenia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
spectrum of mutations VPS13B
Time Frame: baseline
|
baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 24, 2013
Primary Completion (Actual)
September 13, 2016
Study Completion (Actual)
September 13, 2016
Study Registration Dates
First Submitted
July 17, 2013
First Submitted That Met QC Criteria
July 22, 2013
First Posted (Estimate)
July 25, 2013
Study Record Updates
Last Update Posted (Actual)
January 31, 2018
Last Update Submitted That Met QC Criteria
January 30, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OLIVIER-FAIVRE PHRC N 2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cohen Syndrome
-
X4 PharmaceuticalsRecruitingNeutropeniaUnited States, France, Spain, Thailand, United Kingdom, Belgium, Italy, Germany, Romania, Hungary, Israel, Greece, Australia, Serbia, Czechia, Georgia, Argentina, Portugal, Ukraine, Canada, Switzerland, Malaysia, Turkey (Türkiye), Col... and more
-
GlaxoSmithKlineNot yet recruiting
-
Rutgers, The State University of New JerseyRecruitingMicrodeletion 3q29 Syndrome | Microduplication 3q29 SyndromeUnited States
-
Lokman Hekim UniversityCompletedSubacromial Impingement Syndrome | Shoulder Impingement Syndrome | Rotator Cuff Impingement SyndromeTurkey (Türkiye)
-
Neumedicines Inc.Department of Health and Human ServicesCompletedHematopoietic Syndrome Due to Acute Radiation SyndromeUnited States
-
Unravel Biosciences, Inc.RecruitingPitt Hopkins SyndromeColombia
-
Cairo UniversityCompleted
-
Cairo UniversityCompleted
-
Ministry of Public Health, Democratic Republic...National Institutes of Health (NIH); Oregon Health and Science University; National... and other collaboratorsCompletedNeurotoxicity Syndrome, Cassava | Neurotoxicity Syndrome, Cyanate | Neurotoxicity Syndrome, Cyanide | Neurotoxicity Syndrome, ThiocyanateCongo, The Democratic Republic of the